|
Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Aedeona
(AMEX:AEN)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Cardiogenics Holdings,
Inc.
(OTC:CGNH)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
Digital
Angel Corporation
(AMEX:DOC)
Dynavax Technologies
Corporation
(NASDAQ:DVAX)
Elan
Corporation
(NYSE: ELN)
Galapagos NV
(Euronext:GLPGA)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Lpath, Inc.
(OTC:LPTN)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware
Information Systems, Inc. (NASDAQ: MEDW)
Redpoint Bio Corporation
(OTC:RPBC)
VIA Pharmaceuticals,
Inc.
(NASDAQ: VIAP)
ZIOPHARM, INC.
(NASDAQ:ZIOP)
| |
About
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc. is a biotechnology company
focused on the development of compounds for the treatment of cardiovascular
and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant
unmet medical need: reducing inflammation in plaque, which is an underlying
cause of atherosclerosis and its complications, including heart attack and
stroke. In addition, VIA's pipeline of drug candidates includes other compounds
to address other underlying causes of cardiovascular disease: high cholesterol,
diabetes and inflammation.
COMPANY
NEWS |
COMPANY WEBSITE |SEC
FILINGS | STOCK
QUOTE
|